Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
- PMID: 27603368
- PMCID: PMC5023891
- DOI: 10.1097/MD.0000000000004727
Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
Abstract
We aimed to estimate overall and cause-specific excess mortality of HIV-positive patients compared with the general population, and to assess the effect of risk factors.We included patients aged >19 years, recruited from January 1, 2004 to May 31, 2014 in Cohort of the Spanish Network on HIV/AIDS Research. We used generalized linear models with Poisson error structure to model excess mortality rates.In 10,340 patients, 368 deaths occurred. Excess mortality was 0.82 deaths per 100 person-years for all-cause mortality, 0.11 for liver, 0.08 for non-AIDS-defining malignancies (NADMs), 0.08 for non-AIDS infections, and 0.02 for cardiovascular-related causes. Lower CD4 count and higher HIV viral load, lower education, being male, and over 50 years were predictors of overall excess mortality. Short-term (first year follow-up) overall excess hazard ratio (eHR) for subjects with AIDS at entry was 3.71 (95% confidence interval [CI] 2.66, 5.19) and 1.37 (95% CI 0.87, 2.15) for hepatitis C virus (HCV)-coinfected; medium/long-term eHR for AIDS at entry was 0.90 (95% CI 0.58, 1.39) and 3.83 (95% CI 2.37, 6.19) for HCV coinfection. Liver excess mortality was associated with low CD4 counts and HCV coinfection. Patients aged ≥50 years and HCV-coinfected showed higher NADM excess mortality, and HCV-coinfected patients showed increased non-AIDS infections excess mortality.Overall, liver, NADM, non-AIDS infections, and cardiovascular excesses of mortality associated with being HIV-positive were found, and HCV coinfection and immunodeficiency played significant roles. Differential short and medium/long-term effects of AIDS at entry and HCV coinfection were found for overall excess mortality.
Conflict of interest statement
The authors report no conflicts of interest.
Figures


Similar articles
-
Overall and cause-specific mortality in HIV-positive subjects compared to the general population.J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19711. doi: 10.7448/IAS.17.4.19711. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397458 Free PMC article.
-
Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.Ann Hepatol. 2013 Mar-Apr;12(2):228-35. Ann Hepatol. 2013. PMID: 23396734
-
Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.Clin Infect Dis. 2006 May 15;42(10):1481-7. doi: 10.1086/503569. Epub 2006 Apr 12. Clin Infect Dis. 2006. PMID: 16619163
-
Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART.AIDS. 2006 Jan 2;20(1):111-6. doi: 10.1097/01.aids.0000196164.71388.3b. AIDS. 2006. PMID: 16327326
-
Advances in the management of HIV/HCV coinfection.Hepatol Int. 2016 May;10(3):424-35. doi: 10.1007/s12072-015-9691-4. Epub 2016 Jan 12. Hepatol Int. 2016. PMID: 26758592 Review.
Cited by
-
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.J Int AIDS Soc. 2022 Dec;25(12):e26048. doi: 10.1002/jia2.26048. J Int AIDS Soc. 2022. PMID: 36562643 Free PMC article.
-
Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV.J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):220-227. doi: 10.1097/QAI.0000000000002325. J Acquir Immune Defic Syndr. 2020. PMID: 32049771 Free PMC article.
-
Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings.AIDS. 2019 Dec 15;33 Suppl 3(Suppl 3):S271-S281. doi: 10.1097/QAD.0000000000002387. AIDS. 2019. PMID: 31800404 Free PMC article.
-
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.AIDS. 2022 Feb 1;36(2):161-168. doi: 10.1097/QAD.0000000000003132. AIDS. 2022. PMID: 34934017 Free PMC article. Review.
-
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.Ann Intern Med. 2020 Oct 6;173(7):536-541. doi: 10.7326/M20-3689. Epub 2020 Jun 26. Ann Intern Med. 2020. PMID: 32589451 Free PMC article.
References
-
- May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health 2011; 8:526–533. - PubMed
-
- Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121–130. - PubMed
-
- Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27–34. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials